YD Bio Limited Warrant logo

YD Bio Limited Warrant (YDESW)

Market Closed
27 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
0. 29
+0.05
+19.3907%
$
805.14K Market Cap
- P/E Ratio
- Div Yield
406 Volume
- Eps
$ 0.24
Previous Close
Investors:
Add Transaction
Day Range
0.26 0.29
Year Range
0.2 2.85
Want to track YDESW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

YDESW closed today higher at $0.29, an increase of 19.3907% from yesterday's close, completing a monthly increase of 10.4762% or $0.03. Over the past 12 months, YDESW stock lost -70.8543%.
YDESW is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

YDESW Chart

People also search for

GreenLight Biosciences Holdings
$ 0.3
-0.0334%
Sify Technologies Limited Rights expiring 6/21/2024
$ 0.18
+2.0571%
Quantum-Si Inc.
$ 0.2
0%
Lumos Pharma Inc
$ 4.34
0%
Mural Oncology plc
$ 2.04
0%

YD Bio Limited Warrant Investors

Name Quantity Cost Value Profit ($) Gain (%)
BO
Brian Oliveira Clear Street Group Inc.
102,358 $205,885.78 $29,683.82 -$176,201.96 -85.58%
Courtney Haddad
Courtney Haddad Concurrent Investment Advisors, LLC
17,672 $37,642 $4,292.53 -$33,349.47 -88.6%

YD Bio Limited Warrant (YDESW) FAQ

What is the stock price today?

The current price is $0.29.

On which exchange is it traded?

YD Bio Limited Warrant is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is YDESW.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 805.14K.

Has YD Bio Limited Warrant ever had a stock split?

No, there has never been a stock split.

YD Bio Limited Warrant Profile

Biotechnology Industry
Healthcare Sector
Ethan Shen CEO
NASDAQ (NMS) Exchange
G9835J103 CUSIP
TW Country
15 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

YD Bio Ltd. is a pioneering biotechnology company dedicated to the development of advanced detection and therapeutic technologies. Founded on February 6, 2024, the company is based in Taipei, Taiwan. YD Bio aims to enhance healthcare outcomes through innovative solutions, focusing on critical areas such as cancer detection, regenerative ophthalmology, and exosome science. With a commitment to research and development, the company is positioning itself at the forefront of medical technology.

Products and Services

  • Cancer Detection Products

    YD Bio offers a range of advanced cancer detection products designed to identify various types of cancer at early stages. Utilising state-of-the-art biomarkers and diagnostic technologies, these products aim to improve the accuracy of cancer screenings and facilitate timely interventions for better patient outcomes.

  • Regenerative Ophthalmology Products

    The company develops regenerative ophthalmology products that focus on repairing and restoring vision. Leveraging cutting-edge research in tissue regeneration and cell therapy, these products aim to treat eye diseases and conditions, enhancing quality of life for patients suffering from vision impairments.

  • Exosome Science

    YD Bio delves into exosome science, which explores the role of exosomes in cell communication and disease progression. Through innovative research, YD Bio is working on harnessing the potential of exosomes for therapeutic applications, including their use in drug delivery and as biomarkers for various diseases.

Contact Information

Address: No. 3, Xingnan St.
Phone: +82 2 546 1611